Acute myeloid leukemia
Conditions
Interventions
Test group:Mitoanthraquinone hydrochloride liposomes combined with azacytidine and Venecla regimen
Sponsors
Tangdu Hospital, Fourth Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients are fully aware of this study and voluntarily participate and sign an informed consent form. 2.Age >=18 years old. 3.The initial treatment of acute myeloid leukemia (non-APL) diagnosed by clinical diagnosis. 4.Normal heart function Y heart ejection fraction >=50%. 5.Liver and kidney function: Alanine aminotransferase (ALT) and aspartic acid aminotransferase (AST) <=2.5 times the upper limit of normal value (ULN) (<=5 times the upper limit of normal value for patients with liver infiltration), total bilirubin <=1.5 times the upper limit of normal value, serum creatinine <=1.5 times the upper limit of normal value. 6.Eastern Oncology Collaborative Group (ECOG) Physical fitness Score: 0-2 points.
Exclusion criteria
Exclusion criteria: 1.Those who have suffered from other malignant tumors in the past or are in need of treatment at the same time. 2.Uncontrollable systemic diseases: such as uncontrollable high blood pressure due to active infections in the progressive stage. 3.Suffering from leukemia of the central nervous system. 4.There is a known history of immediate or delayed hypersensitivity to similar drugs and excipients of the studied drugs. 5.Patients who refused to take effective contraceptive measures during the study of pregnant and lactating women. 6.Accompanied by a history of severe nervous or mental illness. 7.There are other serious diseases such as severe myocardial infarction or unstable angina pectoris and severe arrhythmia. 8.Cerebrovascular events: including transient cerebral ischemia, etc. 9.Subjects who are known to be infected with human immunodeficiency virus, hepatitis B, hepatitis C active infection, carriers of inactive hepatitis, or subjects with low titers of viral hepatitis virus after treatment with non-banned antiviral drugs will not be excluded. 10.Subjects who received strong or moderate CYP3A inducers/inhibitors or strong P-gp inhibitors or related foods within 7 days before starting the study treatment. 11.Patients who cannot take oral drugs or have malabsorbent syndrome. 12.The researchers judged that there were patients who were not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compound remission rate after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Micro-residual disease to negative rate;1-year event-free survival rate;1-year overall survival rate;Hematological and non-hematological toxicity; | — |
Countries
China
Contacts
Public ContactWeiwei Qin
Tangdu Hospital, Fourth Military Medical University
Outcome results
None listed